Slide 1: Third quarter 2025 financial results and business update
Pharming Group N.V. Third quarter 2025 financial results and business update November 6, 2025 NASDAQ: PHAR | EURONEXT Amsterdam: PHARM
Slide 2: Introduction
CEO Fabrice Chouraqui Chief Executive Officer Introduction
Slide 3: Speakers
SPEAKERS Fabrice Chouraqui Stephen Toor Anurag Relan, MD Kenneth Lynard Chief Executive Officer Chief Commercial Officer Chief Medical Officer Chief Financial Officer
Slide 4: Forward-looking statements
Forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual resu
Slide 5: Strong third quarter 2025 performance
Strong third quarter 2025 performance Revenues RUCONEST Joenja Amounts in US$ million 97.3 • Total revenues up 30% 15.1 74.8 11.2 • Significant growth in operating profit 82.2 63.6 • Significant cash flow from operations – US$32 million 3Q 2024 3Q 2025 • High double-digit Joenja® and RUCONEST® reven
Slide 6: Combination of commercial and pipeline assets poised to deliver strong value creation
Combination of commercial and pipeline assets poised to deliver strong value creation Commercial Pipeline RUCONEST® HAE Unique value proposition/positioning Highly specific manufacturing process PIDs Joenja® for APDS Leniolisib for PIDs / CVID > $1B with immune Significant near-term catalysts revenu
Slide 7: Vision for the future
Vision for the future Develop a leading global rare disease company with a diverse portfolio and presence in large markets, leveraging proven and efficient clinical development, supply chain, and commercial infrastructure 7
Slide 8: Commercial update
CCO Stephen Toor Chief Commercial Officer Commercial update
Slide 9: RUCONEST strong growth continues in acute HAE market
RUCONEST® strong growth continues in acute HAE market RUCONEST® revenues RUCONEST® U.S. new prescribers • Strong U.S. in-market demand ₋ Continuing to add prescribers and patients Amounts in US$ million 82.2 26 ₋ New patient enrollments 24 remain high (~60) 22 22 63.6 20 20 ₋ Increase in more severe
Slide 10: RUCONEST unique value proposition and positioning
RUCONEST® unique value proposition and positioning Type 1, Type 2, and Normal C1-INH HAE patients rely on RUCONEST® • Only recombinant C1-INH protein replacement therapy • Targets the root cause of HAE across all pathways • IV administration – rapid onset, high dose Time of taking 4 hours after 24 h
Slide 11: Joenja strong double-digit growth in 12y+ APDS segment
Joenja® strong double-digit growth in 12y+ APDS segment Joenja® revenues US patients on Joenja® 116 • Strong YoY increase in APDS 114 patients on therapy in the US Amounts in US$ million 15.1 102 ➢ 116 patients (+25% vs 3Q24) 96 11.2 91 93 • Acceleration of U.S. APDS patient 83 identification ➢ +13
Slide 12: Joenja APDS pediatric label expansion – go to market strategy
Joenja® APDS pediatric label expansion – go to market strategy Children 4-11 years old with APDS FDA Priority Review with PDUFA date of Jan 31, 2026* FDA filing based on Phase III data consistent with the improvements and safety seen in the previously reported randomized controlled trial in adolesce
Slide 13: R&D update
CMO Anurag Relan, MD Chief Medical Officer R&D update
Slide 14: Executing on high value rare disease pipeline
Executing on high value rare disease pipeline Leniolisib sNDA for 4-11 yo APDS patients – FDA Priority Review, Jan. 26 PDUFA APDS Japan, EMA and other regulatory reviews on track for 2026 approvals PIDs with immune Genetic PID and CVID Phase II POC trials on track for 2H 2026 read-outs dysregulation
Slide 15: Activities surrounding expanded APDS prevalence
Activities surrounding expanded APDS prevalence Findings >100 new PI3Kδ gain of function (GOF) variants identified in Cell paper Carriers of these variants were found in population databases with prevalence up to 100X higher than current APDS estimates Associated patient phenotypes more diverse than
Slide 16: Scientific presentations at ACAAI showcase new data across our portfolio
Scientific presentations at ACAAI showcase new data across our portfolio 12 abstracts accepted for presentation at ACAAI Scientific Meeting November 6-10, 2025 RUCONEST® (rhC1INH) for HAE 5 Joenja® for APDS 7 posters posters Clinical Trial Re-Analysis Burden of disease • Onset of symptom relief • Im
Slide 17: Financials and outlook
CEO Kenneth Lynard Chief Financial Officer Financials and outlook
Slide 18: Financial highlights: 3Q 2025 vs 3Q 2024
Financial highlights: 3Q 2025 vs 3Q 2024 Revenues Adjusted (Non-GAAP) Cash flow from operations RUCONEST Joenja Operating profit (loss)* Amounts in US$ million Amounts in US$ million Amounts in US$ million 97.3 15.1 32.0 74.8 11.2 16.0 82.2 9.7 63.6 4.1 3Q 2024 3Q 2025 3Q 2024 3Q 2025 3Q 2024 3Q 202
Slide 19: Financial highlights: 9M 2025 vs 9M 2024
Financial highlights: 9M 2025 vs 9M 2024 Revenues Adjusted (Non-GAAP) Cash flow from operations RUCONEST Joenja Operating profit (loss)* Amounts in US$ million Amounts in US$ million Amounts in US$ million 269.6 44.0 38.4 29.7 204.5 31.9 231.2 172.6 (11.1) (15.3) 9M 2024 9M 2025 9M 2024 9M 2025 9M
Slide 20: 2025 financial guidance and long-term capital outlook
2025 financial guidance and long-term capital outlook Revenue and operating expenses: FY 2025 Guidance Notes Total Revenues US$365 - 375 million 23 - 26% growth • Assumes constant currency Operating Expenses • Includes $10.2 million non-recurring Abliva- US$304 - 308 million related transaction and
Slide 21: Conclusion
CEO Fabrice Chouraqui Chief Executive Officer Conclusion
Slide 22: Building a leading global rare disease biopharma company
Building a leading global rare disease biopharma company Strong Q3 growth Upgraded High value Significant momentum financial outlook pipeline catalysts High double-digit Raised 2025 revenue Joenja® (leniolisib) for Joenja® for APDS: revenue growth for guidance to PIDs/CVID with VUSs, pediatric label
Slide 23: Q&A
Q&A Fabrice Chouraqui Stephen Toor Anurag Relan, MD Kenneth Lynard Chief Executive Officer Chief Commercial Officer Chief Medical Officer Chief Financial Officer
Slide 24: www.pharming.com
www.pharming.com NASDAQ: PHAR | EURONEXT Amsterdam: PHARM
Slide 25: Appendix
Pharming Group N.V. Appendix
Slide 26: Statement of profit and loss
Statement of profit and loss 26
Slide 27: Balance sheet — assets
Balance sheet — assets wunts in | 0 Non-current assets September 30, 2025 December 31, 2024 Intangible assets 134,926 61,039 Property, plant and equipment 7,475 7,752 Right-of-use assets 17,517 16,382 Long-term prepayments 95 90 Deferred tax assets 27,485 30,544 Investment accounted for using the eq
Slide 28: Balance sheet – liabilities
Balance sheet – liabilities 28
Slide 29: Cash flow (1/2)
Cash flow (1/2) Pharming’ 9M 2025 (loss) before tax 8,049| (15,170) ‘Adjustments to reconcile net profit (loss) to net cash used in operating activities: Pro’ Depreciation, amortization, impairment of non-current assets 8,010 8,371 Equity settled share based payments 9,256 8,605 Fair value loss (gai
Slide 30: Cash flow (2/2)
Cash flow (2/2) Pharming’ Capital expenditure for property, plant and equipment (480) (660) investment intangible assets (6) = Disposal of investment designated as at FVOC! — 1,972 Investment in associates using the equity method (731) = Purchases of marketable securities —| (222,249) Proceeds from